DE60041367D1 - Vaskuläre Endothelzellen Wachstumsfaktor (VEGF) Varianten und dessen Verwendungen - Google Patents

Vaskuläre Endothelzellen Wachstumsfaktor (VEGF) Varianten und dessen Verwendungen

Info

Publication number
DE60041367D1
DE60041367D1 DE60041367T DE60041367T DE60041367D1 DE 60041367 D1 DE60041367 D1 DE 60041367D1 DE 60041367 T DE60041367 T DE 60041367T DE 60041367 T DE60041367 T DE 60041367T DE 60041367 D1 DE60041367 D1 DE 60041367D1
Authority
DE
Germany
Prior art keywords
vegf
variants
growth factor
cell growth
vascular endothelial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60041367T
Other languages
German (de)
English (en)
Inventor
Brian Cunningham
Abraham Devos
Bing Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE60041367D1 publication Critical patent/DE60041367D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE60041367T 1999-04-16 2000-04-10 Vaskuläre Endothelzellen Wachstumsfaktor (VEGF) Varianten und dessen Verwendungen Expired - Lifetime DE60041367D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12978899P 1999-04-16 1999-04-16
US18423500P 2000-02-23 2000-02-23

Publications (1)

Publication Number Publication Date
DE60041367D1 true DE60041367D1 (de) 2009-02-26

Family

ID=26827914

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60028565T Expired - Lifetime DE60028565T2 (de) 1999-04-16 2000-04-10 Vaskuläre endothelzellen wachstumsfaktor (vegf) varianten und dessen verwendungen
DE60041367T Expired - Lifetime DE60041367D1 (de) 1999-04-16 2000-04-10 Vaskuläre Endothelzellen Wachstumsfaktor (VEGF) Varianten und dessen Verwendungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60028565T Expired - Lifetime DE60028565T2 (de) 1999-04-16 2000-04-10 Vaskuläre endothelzellen wachstumsfaktor (vegf) varianten und dessen verwendungen

Country Status (15)

Country Link
US (1) US20060063203A1 (enExample)
EP (2) EP1655368B1 (enExample)
JP (1) JP2002541849A (enExample)
KR (1) KR100634926B1 (enExample)
CN (1) CN1328376C (enExample)
AT (2) ATE420177T1 (enExample)
AU (1) AU771042B2 (enExample)
CA (1) CA2370246C (enExample)
DE (2) DE60028565T2 (enExample)
ES (2) ES2320367T3 (enExample)
HU (1) HU228898B1 (enExample)
IL (2) IL145675A0 (enExample)
MX (1) MXPA01010469A (enExample)
NZ (1) NZ514488A (enExample)
WO (1) WO2000063380A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
CA2385665A1 (en) * 1999-11-02 2001-05-10 Genentech, Inc. Modulation of enos activity and therapeutic uses thereof
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
WO2003084574A1 (en) 2002-03-01 2003-10-16 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US20050100963A1 (en) 2002-03-01 2005-05-12 Dyax Corporation KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7211240B2 (en) * 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
ES2506142T3 (es) * 2002-03-01 2014-10-13 Dyax Corp. Péptidos de unión a KDR y a VEGF/KDR y su uso en diagnóstico
EP2430923A1 (en) 2002-06-05 2012-03-21 Genentech, Inc. Compositions and methods for liver growth and liver protection
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
EP2526960A1 (en) 2003-03-12 2012-11-28 Genentech, Inc. Use of BV8 and/or EG-VEGF to promote hematopoiesis
WO2006014729A2 (en) 2004-07-20 2006-02-09 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
LT1781698T (lt) 2004-07-20 2016-09-26 Genentech, Inc. Į angiopoetiną panašaus baltymo 4 kompozicijos ir panaudojimo būdai
CN102614134B (zh) 2005-03-25 2016-09-07 瑞泽恩制药公司 Vegf拮抗剂制剂
WO2007109183A2 (en) * 2006-03-20 2007-09-27 Novartis Ag Mutations and polymorphisms of fms-related tyrosine kinase 1
RU2432155C3 (ru) 2006-06-16 2017-11-17 Ридженерон Фармасьютикалз, Инк. Составы антагониста vegf, подходящие для интравитреального введения

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US169292A (en) * 1875-10-26 Improvement in butter-packages
DK0751992T3 (da) * 1994-03-08 2006-03-06 Human Genome Sciences Inc Karendotelvækstfaktor 2
CN1185159A (zh) * 1995-06-06 1998-06-17 人体基因组科学有限公司 人血管内皮生长因子3
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US6750044B1 (en) * 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids

Also Published As

Publication number Publication date
EP1655368A1 (en) 2006-05-10
ATE420177T1 (de) 2009-01-15
WO2000063380A1 (en) 2000-10-26
DE60028565D1 (de) 2006-07-20
EP1171594A1 (en) 2002-01-16
KR20020008151A (ko) 2002-01-29
ES2320367T3 (es) 2009-05-21
EP1171594B1 (en) 2006-06-07
IL145675A0 (en) 2002-06-30
HK1093218A1 (en) 2007-02-23
CA2370246A1 (en) 2000-10-26
AU771042B2 (en) 2004-03-11
CN1352684A (zh) 2002-06-05
NZ514488A (en) 2004-01-30
JP2002541849A (ja) 2002-12-10
EP1655368B1 (en) 2009-01-07
KR100634926B1 (ko) 2006-10-17
ES2265931T3 (es) 2007-03-01
IL145675A (en) 2010-11-30
HU228898B1 (en) 2013-06-28
AU4222000A (en) 2000-11-02
US20060063203A1 (en) 2006-03-23
DE60028565T2 (de) 2007-06-06
ATE329024T1 (de) 2006-06-15
MXPA01010469A (es) 2002-07-30
HUP0200827A3 (en) 2004-11-29
HUP0200827A2 (en) 2002-06-29
CN1328376C (zh) 2007-07-25
CA2370246C (en) 2017-03-21

Similar Documents

Publication Publication Date Title
DE60041367D1 (de) Vaskuläre Endothelzellen Wachstumsfaktor (VEGF) Varianten und dessen Verwendungen
ATE314395T1 (de) Humanisierte antikörper und verfahren zu ihrer herstellung
IL143596A0 (en) Vascular endothelial cell growth factor antagonists and uses thereof
ATE110108T1 (de) Genetische modifizierung von endothelialen zellen.
DK0851920T3 (da) Varianter af vaskulær endotelcellevækstfaktor, anvendelser af disse samt fremgangsmåder til fremstilling deraf
FR05C0020I2 (fr) Anticorps anti-VEGF
BG103232A (en) Heterocyclic esters and amides
UA105625C2 (uk) Пастка vegf і її терапевтичне застосування
DK0939767T3 (da) Procin faktor VIII og hybrider deraf
DK1181319T3 (da) Kimære DR4-antistoffer og anvendelser deraf
DK0922102T3 (da) Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf
EP1746160A3 (en) Hepatocyte growth factor receptor antagonists and uses thereof
DK1129186T3 (da) Et faktor VIII-polypeptid med faktor VIII:C-aktivitet
DE69505804D1 (de) Afamin: ein menschliches serum albumin ähnliches protein
DK0795605T3 (da) Denatureret lavdensitetslipoprotein-receptor
DE59707813D1 (de) Rezeptorbindungsassay, für den rezeptorbindungsassay geeigneter rekombinanter fusionsrezeptor, vektor zu dessen herstellung sowie reagenziensatz für die durchführung des rezeptorbindungsassays
ATE265234T1 (de) Pharmazeutische zusammensetzung von hydrophob modifizierten hedgehog-proteinen und deren verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition